EphA5

EphA5

EphA5 Informations sur la molécule

Molecule Name
EPH Receptor A5
Alias de la molécule
Ephrin type-A receptor 5
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
EPHA5,BSK,EphA5,EC 2.7.10,Receptor Protein-Tyrosine Kinase HEK7,Tyrosine-Protein Kinase Receptor EHK-1,Epididymis Secretory Sperm Binding Protein,EK7,Hek7,EHK-1,EC 2.7.10.1,EPH-like kinase 7,EPH-Like Kinase,EPH homology kinase 1,Brain-Specific Kinase,EPH Homology Kinase,Ephrin type-A receptor 5,Ephrin Type-A Receptor,HEK7,CEK7,EHK1,TYRO4
Contexte de la molécule
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance.

EphA5 Liste de produits

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
EphA5
Human EphA5 Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
SPR

$360.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
MBRC-101MBRC-101Phase 2 ClinicalMBrace Therapeutics Inc
Neoplasms
Details
Customer Reviews